Edesa Biotech (EDSA) furnishes full-year 2025 financial results press release

Rhea-AI Filing Summary

Edesa Biotech, Inc. filed a current report to disclose that on December 12, 2025 it issued a press release announcing its financial results for the fiscal year ended September 30, 2025. The press release is included as Exhibit 99.1 and is furnished, rather than filed, so it is not automatically subject to certain Exchange Act liabilities or incorporated into other SEC reports unless specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 12/12/2025 - 04:25 PM Learn about SEC filing dates

FAQ

What did Edesa Biotech (EDSA) report in this 8-K filing?

Edesa Biotech reported that it issued a press release announcing its financial results for the fiscal year ended September 30, 2025, and attached that release as an exhibit.

Which period do the reported Edesa Biotech (EDSA) results cover?

The financial results discussed in the press release cover Edesa Biotech’s fiscal year ended September 30, 2025.

What exhibits are included with Edesa Biotech’s (EDSA) current report?

The filing includes Exhibit 99.1, which is the press release dated December 12, 2025, and Exhibit 104, the cover page interactive data file.

Is the Edesa Biotech (EDSA) earnings press release considered filed with the SEC?

No. The company states the press release is furnished, not filed, so it is not automatically subject to certain Exchange Act Section 18 liabilities or incorporated into other filings unless specifically referenced.

Where can investors find the detailed Edesa Biotech (EDSA) FY 2025 results?

The detailed financial results are contained in the press release attached as Exhibit 99.1 to the current report.

False000154015900015401592025-12-122025-12-12iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  December 12, 2025

_______________________________

EDESA BIOTECH, INC.

(Exact name of registrant as specified in its charter)

_______________________________

British Columbia, Canada	001-37619	N/A
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

100 Spy Court

Markham, Ontario L3R 5H6

(Address of Principal Executive Offices) (Zip Code)

(289) 800-9600

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares	EDSA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On December 12, 2025, Edesa Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended September 30, 2025 (the “Earnings Release”). The full text of the Earnings Release is attached hereto as Exhibit 99.1. The information furnished herein and therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Edesa Biotech, Inc. dated December 12, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EDESA BIOTECH, INC.
Date: December 12, 2025	By:	/s/ Peter J. Weiler
		Peter J. Weiler
		Chief Financial Officer